Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk DiseaseMatthew S. Davids, Jennifer R. Brown, Yue Ren et al.|Blood|2024Cited by 0